文献速递临床试验与 GCP基础与转化研究

含硼化合物与油酰乙醇胺补充对COVID-19患者康复趋势影响的研究方案

Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-10-27

本研究为单中心、随机、双盲、安慰剂对照临床试验,计划纳入40例确诊SARS-CoV-2感染的成年患者,随机分为四组,分别接受含硼化合物、油酰乙醇胺、两者联合或仅常规治疗,旨在评估补充剂对临床症状和炎症指标恢复的影响。

要点

  • 含硼化合物(5 mg)与油酰乙醇胺(200 mg)每日两次补充两周。
  • 主要终点为两周内临床症状(发热、干咳、乏力)和炎症指标恢复。
  • 试验注册于伊朗临床试验注册中心(IRCT20090609002017N35)。

核心结论

  • 研究旨在评估含硼化合物和油酰乙醇胺补充对COVID-19患者康复趋势的影响。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照临床试验,平行分组设计。
  • 计划纳入40例确诊SARS-CoV-2感染的成年患者,每组10例,分配比1:1。
  • 随机化采用计算机生成的区组随机方案,受试者和研究者均设盲。

关键数值与推荐

  • A组:含5 mg硼化合物胶囊,每日两次,共两周。
  • B组:含200 mg油酰乙醇胺胶囊,每日两次,共两周。
  • C组:含5 mg硼化合物和200 mg油酰乙醇胺的胶囊,每日两次,共两周。
  • D组:仅接受常规治疗,不接受额外补充剂。
  • 主要终点为随机化后两周内临床症状(发热、干咳、乏力)和临床前指标(CBC、ESR、CRP)的恢复情况。

局限性

  • 样本量较小(总计40例),可能影响统计效能和结果外推。
  • 研究仅在一个中心进行,结果可能受当地医疗条件和人群特征影响。
  • 随访时间较短(两周),无法评估长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this study, we investigate the effect of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19. TRIAL DESIGN: The current study is a single-center, randomized, double-blind, placebo-controlled clinical trial with parallel groups. PARTICIPANTS: The inclusion criteria include male and female patients≥18 years of age, with a confirmed diagnosis of SARS-CoV-2 infection via polymerase chain reaction (PCR) and/or antibody test and with written informed consent to participate in this trial. The exclusion criteria include regular use of any other supplement, severe and critical COVID-19 pneumonia, pregnancy and breastfeeding. This study is being conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. INTERVENTION AND COMPARATOR: Patients are randomly assigned to four groups. The first group (A) will take one capsule containing 5 mg of boron compounds twice a day for two weeks. The second group (B) will take one capsule containing 200 mg oleoylethanolamide twice a day for two weeks. The third group (C) will take one capsule containing 5 mg boron compounds with 200 mg oleoylethanolamide twice a day for two weeks, and the fourth group (D) does not receive any additional treatment other than routine treatments. Boron-containing compounds and oleoylethanolamide capsules will be synthesized at Nutrition Research Center of Tabriz University of Medical Sciences. MAIN OUTCOMES: The primary end point of this study is to investigate the recovery rate of clinical symptoms, including fever, dry cough, and fatigue, as well as preclinical features, including complete blood count (CBC), the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) profiles within two weeks of randomization. RANDOMISATION: Patients are randomized into four equal groups in a parallel design (allocation ratio 1:1). A randomized block procedure is used to divide subjects into one of four treatment blocks (A, B, C, and D) by a computer-generated allocation schedule. BLINDING (MASKING): The participants and investigators (enrolling, assessing, and analyzing) are blinded to the intervention assignments until the end of the study and data analysis. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The calculated total sample size is 40 patients, with 10 patients in each group. TRIAL STATUS: The protocol is Version 1.0, May 17, 2020. Recruitment began May 19, 2020, and is anticipated to be completed by October 19, 2020. TRIAL REGISTRATION: This clinical trial has been registered by the title of "Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in Patients with COVID-19: A double-blind randomized placebo-controlled clinical trial" in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20090609002017N35 ", https://www.irct.ir/trial/48058 . The registration date is 17 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tutunchi H, Mobasseri M, Pourmoradian S, et al. Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33109244. doi:10.1186/s13063-020-04820-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。